- Home
- CRDL vs TELA Comparison
CRDL vs TELA Comparison
Compare CRDL & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- TELA
- Stock Information
- Founded
- CRDL 2017
- TELA 2012
- Country
- CRDL Canada
- TELA United States
- Employees
- CRDL N/A
- TELA N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- TELA Medical/Dental Instruments
- Sector
- CRDL Health Care
- TELA Health Care
- Exchange
- CRDL Nasdaq
- TELA Nasdaq
- Market Cap
- CRDL 104.5M
- TELA 112.5M
- IPO Year
- CRDL N/A
- TELA 2019
- Fundamental
- Price
- CRDL $1.23
- TELA $2.63
- Analyst Decision
- CRDL Strong Buy
- TELA Strong Buy
- Analyst Count
- CRDL 3
- TELA 4
- Target Price
- CRDL $9.00
- TELA $9.25
- AVG Volume (30 Days)
- CRDL 298.3K
- TELA 166.5K
- Earning Date
- CRDL 11-14-2024
- TELA 11-07-2024
- Dividend Yield
- CRDL N/A
- TELA N/A
- EPS Growth
- CRDL N/A
- TELA N/A
- EPS
- CRDL N/A
- TELA N/A
- Revenue
- CRDL N/A
- TELA $68,649,000.00
- Revenue This Year
- CRDL N/A
- TELA $30.39
- Revenue Next Year
- CRDL N/A
- TELA $25.51
- P/E Ratio
- CRDL N/A
- TELA N/A
- Revenue Growth
- CRDL N/A
- TELA 29.34
- 52 Week Low
- CRDL $0.96
- TELA $2.30
- 52 Week High
- CRDL $3.12
- TELA $7.84
- Technical
- Relative Strength Index (RSI)
- CRDL 35.88
- TELA 37.77
- Support Level
- CRDL $1.17
- TELA $2.57
- Resistance Level
- CRDL $1.30
- TELA $2.88
- Average True Range (ATR)
- CRDL 0.08
- TELA 0.19
- MACD
- CRDL 0.00
- TELA -0.03
- Stochastic Oscillator
- CRDL 17.65
- TELA 11.34
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About TELA TELA Bio Inc.
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.